The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Dr Kami Maddocks reflects on fresh data, such as the new epcoritamab combo approval, evolving CD19 sequencing data, and ...

Shared decision-making—balancing clinical data with the patient's personal, logistical, and risk-tolerance factors—is ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

As actor Ahn Sung-ki passed away after battling blood cancer, public interest in the disease has surged. The blood cancer Ahn ...